Sanofi’s Fluzone High-Dose Quadrivalent (Influenza Vaccine) Receives the FDA’s Approval for Adults Aged≥ 65yrs.

 Sanofi’s Fluzone High-Dose Quadrivalent (Influenza Vaccine) Receives the FDA’s Approval for Adults Aged≥ 65yrs.

Sanofi’s Fluzone High-Dose Quadrivalent (Influenza Vaccine) Receives the FDA’s Approval for Adults Aged≥ 65yrs.

Shots:

  • The sBLA approval is based on P-III immunogenicity and safety study assessing Fluzone High-Dose Quadrivalent vs two trivalent formulations of Fluzone High-Dose in 32,000 adults aged≥ 65yrs. over two influenza seasons in the US and Canada
  • The P-III results demonstrated that Fluzone High-Dose Quadrivalent prevent 24% more cases of influenza caused by any circulating influenza strain and 51% more cases of influenza caused by strains like those contained in the vaccine
  • The Fluzone High-Dose Quadrivalent contains an additional influenza B strain and has filed sBLA in regulatory bodies outside the US with its anticipated EMA’s approval in H2’20. The vaccine will be available in the US for immunization during the 2020-2021 influenza season

Click here to­ read full press release/ article | Ref: Sanofi | Image: Glassdoor

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post